The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Reuben Dawkins, CEO of Link Biologics, a company developing protein biologics to treat inflammatory and degenerative conditions. Link is currently developing treatments for Dry Eye… Read More
Aldeyra Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The CRL states that there is “a lack of substantial evidence… Read More
CS Pharmaceuticals (CSP) has acquired AxeroVision, a company developing novel therapies for the treatment of dry eye disease (DED) and other ophthalmic inflammatory diseases that address the underlying inflammatory processes. Darren Mercer, Chief Executive of CSP, said: “We are thrilled to acquire AxeroVision, and in particular… Read More
The US Food and Drug Administration (FDA) has approved the Phase III clinical trial design for BRIM Biotechnology’s lead candidate for dry eye disease (DED), BRM421. BRIM will submit the Phase III study protocol to the FDA later this year. BRM421 is a novel, first-in-class regenerative peptide… Read More
